Hisamitsu Pharmaceutical Co., Inc. (TYO:4530)
Japan
· Delayed Price · Currency is JPY 4,005.00
-5.00 (-0.12%)
Jul 8, 2025, 3:30 PM JST
TYO:4530 Income Statement
Financials in millions JPY. Fiscal year is March - February.
Millions JPY. Fiscal year is Mar - Feb.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Feb '25 Feb 28, 2025 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 | Feb '21 Feb 28, 2021 | 2016 - 2020 |
| 156,006 | 141,706 | 128,330 | 120,193 | 114,510 | Upgrade
| |
Revenue Growth (YoY) | 10.09% | 10.42% | 6.77% | 4.96% | -18.78% | Upgrade
|
Cost of Revenue | 64,810 | 62,735 | 55,630 | 50,126 | 45,337 | Upgrade
|
Gross Profit | 91,196 | 78,971 | 72,700 | 70,067 | 69,173 | Upgrade
|
Selling, General & Admin | 61,312 | 57,157 | 51,282 | 50,125 | 47,762 | Upgrade
|
Research & Development | 10,903 | 8,614 | 9,785 | 10,613 | 10,766 | Upgrade
|
Operating Expenses | 72,300 | 65,803 | 61,099 | 60,730 | 58,501 | Upgrade
|
Operating Income | 18,896 | 13,168 | 11,601 | 9,337 | 10,672 | Upgrade
|
Interest Expense | -23 | -18 | -15 | -20 | -10 | Upgrade
|
Interest & Investment Income | 3,993 | 3,684 | 1,872 | 1,058 | 1,406 | Upgrade
|
Earnings From Equity Investments | 590 | 585 | 424 | 569 | 133 | Upgrade
|
Currency Exchange Gain (Loss) | -176 | 1,778 | 1,973 | 1,276 | -542 | Upgrade
|
Other Non Operating Income (Expenses) | 729 | 450 | 195 | 417 | 169 | Upgrade
|
EBT Excluding Unusual Items | 24,009 | 19,647 | 16,050 | 12,637 | 11,828 | Upgrade
|
Gain (Loss) on Sale of Investments | 5,019 | 389 | -257 | 653 | 188 | Upgrade
|
Gain (Loss) on Sale of Assets | 1 | -6 | 320 | -55 | 178 | Upgrade
|
Asset Writedown | -343 | -847 | - | - | - | Upgrade
|
Other Unusual Items | - | 1 | -1 | -280 | 2 | Upgrade
|
Pretax Income | 28,686 | 19,184 | 16,112 | 12,955 | 12,196 | Upgrade
|
Income Tax Expense | 6,385 | 4,754 | 3,987 | 3,093 | 2,764 | Upgrade
|
Earnings From Continuing Operations | 22,301 | 14,430 | 12,125 | 9,862 | 9,432 | Upgrade
|
Minority Interest in Earnings | -543 | -461 | -383 | -204 | -182 | Upgrade
|
Net Income | 21,758 | 13,969 | 11,742 | 9,658 | 9,250 | Upgrade
|
Net Income to Common | 21,758 | 13,969 | 11,742 | 9,658 | 9,250 | Upgrade
|
Net Income Growth | 55.76% | 18.97% | 21.58% | 4.41% | -50.52% | Upgrade
|
Shares Outstanding (Basic) | 74 | 77 | 79 | 81 | 82 | Upgrade
|
Shares Outstanding (Diluted) | 74 | 77 | 79 | 81 | 82 | Upgrade
|
Shares Change (YoY) | -4.27% | -3.03% | -2.29% | -0.63% | -0.56% | Upgrade
|
EPS (Basic) | 295.58 | 181.61 | 148.00 | 118.92 | 113.21 | Upgrade
|
EPS (Diluted) | 295.15 | 181.42 | 147.88 | 118.84 | 113.11 | Upgrade
|
EPS Growth | 62.69% | 22.68% | 24.44% | 5.07% | -50.24% | Upgrade
|
Free Cash Flow | 5,138 | 5,264 | 4,868 | 15,589 | 1,948 | Upgrade
|
Free Cash Flow Per Share | 69.70 | 68.36 | 61.30 | 191.82 | 23.82 | Upgrade
|
Dividend Per Share | 86.000 | 85.000 | 84.000 | 84.000 | 83.500 | Upgrade
|
Dividend Growth | 1.18% | 1.19% | - | 0.60% | 0.60% | Upgrade
|
Gross Margin | 58.46% | 55.73% | 56.65% | 58.29% | 60.41% | Upgrade
|
Operating Margin | 12.11% | 9.29% | 9.04% | 7.77% | 9.32% | Upgrade
|
Profit Margin | 13.95% | 9.86% | 9.15% | 8.04% | 8.08% | Upgrade
|
Free Cash Flow Margin | 3.29% | 3.72% | 3.79% | 12.97% | 1.70% | Upgrade
|
EBITDA | 25,231 | 18,340 | 16,553 | 13,658 | 14,751 | Upgrade
|
EBITDA Margin | 16.17% | 12.94% | 12.90% | 11.36% | 12.88% | Upgrade
|
D&A For EBITDA | 6,335 | 5,172 | 4,952 | 4,321 | 4,079 | Upgrade
|
EBIT | 18,896 | 13,168 | 11,601 | 9,337 | 10,672 | Upgrade
|
EBIT Margin | 12.11% | 9.29% | 9.04% | 7.77% | 9.32% | Upgrade
|
Effective Tax Rate | 22.26% | 24.78% | 24.75% | 23.88% | 22.66% | Upgrade
|
Advertising Expenses | 29,953 | 28,214 | 23,549 | 25,406 | 24,725 | Upgrade
|
Updated Jan 9, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.